Angela M Gronenborn

Title: Angela M Gronenborn: Innovator in Antiviral Research

Introduction

Angela M Gronenborn is a prominent inventor based in Bethesda, MD (US). She has made significant contributions to the field of antiviral research, particularly in the development of methods to combat influenza viral infections. Her innovative work has led to the creation of a patented technology that holds promise for therapeutic applications.

Latest Patents

Angela M Gronenborn holds a patent for "Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins." This invention provides a method for inhibiting influenza viral infections in a host. The method involves instilling a cell that produces an antiviral protein, peptide, or conjugate containing at least nine contiguous amino acids of SEQ ID NO: 2, which are nonglycosylated and exhibit antiviral activity. This innovative approach aims to prevent or treat influenza infections effectively.

Career Highlights

Angela is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. Her work at this esteemed institution has allowed her to focus on groundbreaking research in the field of virology and antiviral therapies.

Collaborations

Angela has collaborated with notable colleagues, including Michael R Boyd and Barry R O'Keefe. These partnerships have enhanced her research efforts and contributed to the advancement of antiviral science.

Conclusion

Angela M Gronenborn is a trailblazer in antiviral research, with her patented methods offering new avenues for combating influenza infections. Her contributions to science and medicine continue to have a lasting impact.